1 / 64

The Pancreas

sal
Download Presentation

The Pancreas

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    1. The Pancreas Aviad Hoffman, MD Demetrius Pertsemlidis, MD October 20, 2005

    2. History Herophilus, a Greek anatomist and surgeon; one of the founders of the ancient school of Medicine in Alexandria, Egypt.

    3. Ruphos, an anatomist - surgeon of Ephesus. “pancreas” - "all flesh" Diabetes, named by Aretaeus Asia Minor, (ca A.D. 81-150).

    5. 1958 – Frederick Sanger determining the molecular structure of insulin.

    6. Anatomy

    9. Embryology

    11. Normal pancreatic duct

    12. Sphincters of the pancreas and bile duct

    13. Annular Pancreas

    15. Arterial supply of the pancreas

    16. Venous drainage of the pancreas

    19. Histology of the pancreas 85% exocrine pancreas 2% endocrine pancreas Regulatory feedback system for digestive enzyme and hormone secretion Coordinated function

    20. The exocrine pancreas

    23. Secretin released from duodenual mucosa in response to acidic chyme passing through the pylorus Major stimulant for HCO3 secretion, buffering gastric acid Provides optimal environment for pancreatic enzymes

    25. Cholecystokinin Released from the jejunum in response to luminal digestion products of fat and protein Major stimulant for enzyme secretion

    26. Neural regulation of exocrine secretion

    27. Regulation of Pancreatic Secretion Neural/Hormonal/Metabolic

    29. Pancreatic secretion Pancreatic juice - 800-1200ml/day Bicarbonate - 60-120meq/l, pH 7.6-8.2 Basal rate 0.2-0.3ml/min, max – 5ml/min (secretin) Chloride secretion varies inversely to bicarbonate Chloride/ Bicarbonate sum is constant Na+ and K+ isotonic and constant

    31. Pancreatic enzymes

    34. Familial pancreatitis Enterokinase Trypsinogen ? Trypsin Deficiency of: pancreatic secretory trypsin inhibitor (PSTI) SPINK

    35. Endocrine pancreas

    36. Pancreatic neuroendocrine peptide products Hormones Islet Cell Functions Insulin ß Decreased gluconeogenesis, glycogenolysis, fatty acid breakdown and ketogenesis    Increased glycogenesis, protein synthesis Glucagon a Opposite effects of insulin; increased hepatic glycogenolysis and gluconeogenesis Somatostatin d Inhibits gastrointestinal secretion    Inhibits cell growth Pancreatic PP Inhibits pancreatic exocrine secretion and secretion polypeptide of insulin stimulated by Vagus Facilitates hepatic effect of insulin Amylin (IAPP) ß Counterregulates insulin secretion and function Pancreastatin ß Decreases insulin and somatostatin release   Increases glucagon release   Decreases pancreatic exocrine secretion d -1, EC, G cells Rare IAPP = islet amyloid polypeptide.

    37. Regulation of neuroendocrine secretion Neural/Hormonal/Metabolic Neural parasympathetic sympathetic Hormonal insulin/glucagon somatostatin GI hormones Metabolic glucose amino acids fatty acids

    42. pancreatitis 300,000 cases/year 10-20% are severe of them up to 30% mortality rate 3 times higher for blacks than whites males more often than females

    43. ?

    44. The Cullen sign is a bluish discoloration around the umbilicus resulting from hemoperitoneum. Severe necrotizing pancreatitis

    45. ?

    46. The Grey-Turner sign is a reddish-brown discoloration along the flanks resulting from retroperitoneal blood dissecting along tissue planes

    47. Etiology Biliary tract disease (38%) Alcohol (35%) Post-ERCP (4%) Trauma (1.5%) Hereditary pancreatitis ( <1%) Hypercalcemia ( <1%) Hypertriglyceridemia ( <1%) Tumor ( <1%) Developmental abnormalities ( <1%) Pancreas divisum / Annular pancreas Postoperative ( <1%)

    48. Drugs (~1.4%) Diuretics furosemide, hydrochlorothiazide, Immunosupresant azathioprine, 6-mercaptopurine, corticosteroids Antibiotics tetracycline, nitrofurantoin, metronidazole, sulfonamides Anti neoplastic asparaginase, cisplatin, cytosine arabinoside sulindac, valproic acid, didanosine, methyldopa, estrogens, pentamidine, 5- ASA, octreotide, methandienone, phenformin, piroxicam, procainamide, colaspase, chlorthalidone, cimetidine, diphenoxylate, ethacrynic acid.

    49. Infection ( <1%) Viral : mumps, Epstein-Barr,coxsackievirus, echovirus, varicella-zoster, and measles, AIDS (opportunistic infections, neoplasms, drugs) Bacterial : Mycoplasma pneumoniae, Salmonella, Campylobacter, and Mycobacterium tuberculosis. Parasites : ascariasis (resulting from the migration of worms in and out of the duodenal papillae).

    50. Tityus trinitatis Toxins

    51. Autoimmune Kidney transplant recipients(1.2-6.8%) Idiopathic (10%)

    52. Pathophysiology Intraductal hypertention Disruption in the normal separation of lysosomal and pancreatic enzymes

    53. Prognostic indicators Glasgow Ranson Balthazar APACHE-II

    54. Cystic neoplasms of the pancreas Serous cystadenoma (32-39%) Mucinous cystadenoma (10-45%) Intraductal Papillary Mucinous Neoplasm (11-33%) Solid-cystic neoplasm (<3-4%) Cystic neuroendocrine neoplasm (rare) Ductal adenoca with cystic degeneration (rare) Acinar-cell cystadenocarcinoma (rare)

    55. Diagnosis Serous and mucinous neoplasms: Mean age 50 yrs Mostly women Asymptomatic (< 75%) Symptoms: Abdominal pain Mass Jaundice Prior pancreatitis

    56. Serous Cystic Neoplasms Most common Minimal malignant potential (< 10 reports) Multiple cysts Polycystic (70%) Oligocystic Honeycomb Central stellate scar/calcification (30%)

    57. Mucinous Cystic Neoplasms Majority in body/tail Thick capsule No communication w/ duct

    58. IPMN Proximal sites Cystic dilatation of main PD or side branch Mucin-filled ampulla

    59. Cystic Pancreatic Lesions

    60. Treatment Serous cystic lesions Resection only for symptoms, or ambiguity Enucleation, central pancreatectomy? Mucinous cystic lesions All require resection 2nd malignant potential Operation based on location IPMN Surgery indicated Total pancreatectomy vs. subtotal w/ frozen section margin

    61. Results Generally favorable 5 yr survival: mucinous cystadenoma > 95% Mucinous ca 17-33% IPMN > 50%; <30% if invasive Surveillance?

More Related